Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

these documents (when they are available) and other documents filed with the SEC at the SEC's website at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting Nuvelo Investor Relations at the email address: ir@nuvelo.com or by phone at 650-517-8000.

In addition to the registration statement and related proxy statement/prospectus, Nuvelo files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Nuvelo, Inc. at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Nuvelo, Inc.'s filings with the SEC are also available to the public from commercial document-retrieval services and at SEC's website at http://www.sec.gov, and from Investor Relations at Nuvelo as described above.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Nuvelo, ARCA and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information regarding the special interests of these directors and e
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm ... quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC International ... “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management platform, ... 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... continuous operation up to 1500 bar. The sanitary design gauge of the NS2006L ... contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the processing ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, April 30,2008, after the market closes. ... at 2:00 p.m. PT, which will be open to ... the company will review,the financial results and discuss other ...
... April 23 Schering-Plough,Corporation (NYSE: SGP ) ... from 12 product franchises in Europe. These agreements ... European Commission as part,of its October 2007 clearance ... from Akzo Nobel N.V., In two separate ...
... Within the First Eight Months Since its Introduction in ... VYVANSE has Achieved Over One Million ... to Significantly Improve the Symptoms of ADHD (Inattention, ... 23 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the ...
Cached Biology Technology:Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 2FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 3FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 4FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 5FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 6FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 7FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 8
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... scientists discovered that some strains of algae, when starved of ... ended, and the discovery lay dormant until people began to ... In the early 2000s, algal fuel production enjoyed a tremendous ... notion of converting "pond scum" to oil. But a recent ...
... in German . Leipzig -- Pesticides are a ... of a study in which scientists analysed data on 500 organic ... revealed that 38 per cent of these chemicals are present in ... scientists writing in the journal Science of the Total Environment ...
... continued commitment to innovation powered Equifax,s placement on the 2011 ... Financial Insights. Out of 100 companies highlighted on this annual ... than one-third of their revenue from the financial services industry. ... (NYSE: EFX ), one of the largest ...
Cached Biology News:WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 3WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 4Pesticides pollute European waterbodies more than previously thought 2Pesticides pollute European waterbodies more than previously thought 3Pesticides pollute European waterbodies more than previously thought 4Equifax Lands Top 20 Spot in 2011 FinTech 100 Ranking 2Equifax Lands Top 20 Spot in 2011 FinTech 100 Ranking 3
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Tachykinin (H-2)...
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
Biology Products: